Advances in PSMA-targeted therapy for prostate cancer

Wang, Fujin; Li, Zhifeng; Feng, Xiaoqian; Yang, Dazhuang; Lin, Mei

doi:10.1038/s41391-021-00394-5

Cited by 55 publications

(36 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RCTs showed that abiraterone and enzalutamide given as an L1 treatment before docetaxel improved outcomes compared with the use of these drugs as an L2 treatment after docetaxel [45]. This explains why patients in our recent RCTs increasingly used the drugs as an L1 treatment.…”

Section: Discussionmentioning

confidence: 86%

177Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Eyben¹,

Kairemo

Fletcher

et al. 2021

Biomedicines

View full text Add to dashboard Cite

In this systematic review and network meta-analysis (NMA), we aimed to assess the benefits and harms of third-line (L3) treatments in randomized controlled trials (RCTs) of patients with metastatic castration-resistant prostate cancer (mCRPC). Two reviewers searched for publications from 1 January 2006 to 30 June 2021. The review analyzed seven RCTs that included 3958 patients and eight treatments. Treatment with prostate-specific membrane antigen (PSMA)-based radioligand therapy (PRLT) resulted in a 1.3-times-higher rate of median PSA decline ≥50% than treatment with abiraterone, enzalutamide, mitoxantrone, or cabazitaxel (p = 0.00001). The likelihood was 97.6% for PRLT to bring about the best PSA response, out of the examined treatments. PRLT resulted in a 1.1-times-higher six-month rate of median radiographic progression-free survival. Treatment with PRLT in the VISION trial resulted in 1.05-times-higher twelve-month median overall survival than L3 treatment with cabazitaxel in other RCTs. PRLT more often resulted in severe thrombocytopenia and less often in severe leukopenia than did cabazitaxel. In conclusion, for patients with mCRPC, L3 treatment with PRLT is highly effective and safe.

show abstract

Section: Discussionmentioning

confidence: 86%

177Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Eyben¹,

Kairemo

Fletcher

et al. 2021

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Prostate-specific membrane antigen (PSMA) is a 100-kDa type II membrane protein, is exclusively overexpressed in prostate cancer, and acts as a glutamate-preferring carboxypeptidase. Its expression is associated with tumor invasiveness [ 85 , 86 ]. PSMA is not only a well-known biomarker but is also a potential therapeutic target in prostate cancer.…”

Section: Role Of Known and Emerging Targets Of Icesmentioning

confidence: 99%

Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy

Shin

Yang

Yoon

et al. 2022

IJMS

View full text Add to dashboard Cite

Cancer is the second leading cause of death worldwide after cardiovascular diseases. Harnessing the power of immune cells is a promising strategy to improve the antitumor effect of cancer immunotherapy. Recent progress in recombinant DNA technology and antibody engineering has ushered in a new era of bispecific antibody (bsAb)-based immune-cell engagers (ICEs), including T- and natural-killer-cell engagers. Since the first approval of blinatumomab by the United States Food and Drug Administration (US FDA), various bsAb-based ICEs have been developed for the effective treatment of patients with cancer. Simultaneously, several potential therapeutic targets of bsAb-based ICEs have been identified in various cancers. Therefore, this review focused on not only highlighting the action mechanism, design and structure, and status of bsAb-based ICEs in clinical development and their approval by the US FDA for human malignancy treatment, but also on summarizing the currently known and emerging therapeutic targets in cancer. This review provides insights into practical considerations for developing next-generation ICEs.

show abstract

“…The use of diagnostic biomarkers, such as the serum prostate-specific antigen (PSA), which is commonly used for PCa screening, prostatic acid phosphate (PAP), and prostate-specific membrane antigen (PSMA), as target antigens in immunotherapy has been investigated [ 32 , 35 ]. Moreover, the scientific community has been interested in combining immunotherapy and targeted therapy to increase the sensitivity of cancer cells to antitumor effects of antineoplastic drugs [ 36 ].…”

Section: Current Status and Limitations Of Therapies For Urological C...mentioning

confidence: 99%

Pharmacometabolomics Applied to Personalized Medicine in Urological Cancers

et al. 2022

View full text Add to dashboard Cite

Prostate cancer (PCa), bladder cancer (BCa), and renal cell carcinoma (RCC) are the most common urological cancers, and their incidence has been rising over time. Surgery is the standard treatment for these cancers, but this procedure is only effective when the disease is localized. For metastatic disease, PCa is typically treated with androgen deprivation therapy, while BCa is treated with chemotherapy, and RCC is managed primarily with targeted therapies. However, response rates to these therapeutic options remain unsatisfactory due to the development of resistance and treatment-related toxicity. Thus, the discovery of biomarkers with prognostic and predictive value is needed to stratify patients into different risk groups, minimizing overtreatment and the risk of drug resistance development. Pharmacometabolomics, a branch of metabolomics, is an attractive tool to predict drug response in an individual based on its own metabolic signature, which can be collected before, during, and after drug exposure. Hence, this review focuses on the application of pharmacometabolomic approaches to identify the metabolic responses to hormone therapy, targeted therapy, immunotherapy, and chemotherapy for the most prevalent urological cancers.

show abstract

Advances in PSMA-targeted therapy for prostate cancer

Cited by 55 publications

References 101 publications

177Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

177Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy

Pharmacometabolomics Applied to Personalized Medicine in Urological Cancers

Contact Info

Product

Resources

About